secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001558370-23-017666
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo appoints James P. Tursi, M.D. to Board effective Nov 1, 2023
--------------------------------------------------------------------

- Dr. Tursi brings 20 years pharma experience, currently EVP Global R&D at Endo International.
- He will serve on the Nominating and Corporate Governance Committee; receives initial 25,000 RSUs and $40k annual cash retainer.
- NeuroBo expects to file IND for DA-1726 (obesity) in coming months and start Phase 1a in H1 2024.
- DA-1241 (NASH) is in a Phase 2a trial; Dr. Tursi's expertise targets large cardiometabolic markets.
- Dr. Tursi's appointment strengthens board with deep R&D and regulatory background in drug development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023017666/0001558370-23-017666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023017666/nrbo-20231101x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer